HOUSTON, December 3, 2025 /PRNewswire/ — Avance Biosciences today announced the opening of its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company's capabilities in potency and functional cell-based assays under GMP compliance [...]
HOUSTON, June 25, 2025 /PRNewswire/ — Avance Biosciences is proud to announce the launch of its Next-Generation Sequencing (NGS) Center of Excellence, a purpose-built facility designed to unify and enhance the company’s sequencing capabilities across all phases of drug development [...]
HOUSTON, Feb. 26, 2025 /PRNewswire/ -- Avance Biosciences, a leading provider of high-quality analytical and bioanalytical services for the pharmaceutical industry, is pleased to announce that it has successfully registered with the Clinical Laboratory Improvement Amendments (CLIA) program. This registration allows Avance Biosciences to operate under its assigned CLIA number and offer high-complexity laboratory testing [...]
HOUSTON, March 2, 2023 /PRNewswire/ -- Avance Biosciences™ (Avance), a leading CRO that provides GLP/CGMP-compliant biological testing services that aid drug development and manufacturing, announced today that it has signed a licensing agreement with SeQure Dx, a cutting-edge gene-editing diagnostics company. This agreement gives Avance access to SeQure Dx’s GUIDE-seq off-target next-generation sequencing (NGS) analysis methods, [...]
HOUSTON, May 5, 2022 /PRNewswire/ -- Avance Biosciences™, a leading CRO providing GLP/GMP-compliant assay development, assay validation, and sample testing services supporting biological drug development and manufacturing, announced today completion of move-in and validation of an additional 26,000 square feet of laboratory space acquired in the past year. Avance also announced expanded offerings of validated [...]
SOUTH SAN FRANCISCO, February 2, 2021 — Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced today the first tech transfer of a clinical trial-ready cell and gene therapy (CGT) assay from its Tapestri Platform to Avance Biosciences™, Inc., a leading-edge CRO based in Houston [...]
HOUSTON, Feb. 16, 2021 /PRNewswire/ -- Avance Biosciences™, a leading CRO providing GLP/GMP-compliant assay development, assay validation, and sample testing services supporting biological drug development and manufacturing, announced today that its Houston facility [...]
HOUSTON, Dec. 20, 2020 /-- Pharm Tech Outlook, a highly respected pharmaceutical/biotech industry magazine, has recognized Avance Biosciences™ as a top 10 Genomics Solutions Company for 2020. [...]
HOUSTON, Oct. 30, 2018 - Avance Biosciences™, Inc., a leading biological testing company supporting drug development and manufacturing, announced today that its Houston facility was inspected by the U.S. Food and Drug Administration on October 01 through October 04, 2018. This inspection focused on the firm’s quality management system, operation procedures, and data integrity, as [...]
